The need to optimize chemotherapy regimens for chemo-immunotherapy

J Thorac Dis. 2022 Sep;14(9):3648-3649. doi: 10.21037/jtd-22-1101.

Authors

Kentaro Inamura^{1

2}, Yasuyuki Shigematsu^{1

2}

Affiliations

¹ Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
² Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

No abstract available